Zelira Therapeutics Balances Cash Flow
Company Announcements

Zelira Therapeutics Balances Cash Flow

Zelira Therapeutics Ltd. (AU:ZLD) has released an update.

Zelira Therapeutics Limited reported a net decrease in cash from operating activities, totaling $1,183,000 for the current quarter and an accumulated deficit of $2,916,000 over the past nine months. Despite these operating losses, the company secured a net cash inflow from financing activities amounting to $1,231,000 this quarter, primarily through HOPE SPV funding. Overall, Zelira experienced a slight increase in cash and cash equivalents with a $65,000 rise for the quarter.

For further insights into AU:ZLD stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Australian Auto-Generated NewsdeskZelira Therapeutics’ Financials: Borrowings Boost Cash Flow
TipRanks Australian Auto-Generated NewsdeskZelira Therapeutics Advances in FDA Trials and Product Development
TipRanks Australian Auto-Generated NewsdeskZelira Therapeutics Schedules Hybrid 2024 AGM
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App